ArticleFrontiers in bioengineering and biotechnology2026
Biofunctionalization of mineralized collagen with platelet-rich plasma enhances osteogenesis in critical-sized bone defects.
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone defects caused by fractures, nonunion, tumors, or infections severely impair patient quality of life. Although autologous bone grafting remains the gold standard, its limited donor availability and additional surgical trauma have driven the development of biomimetic substitutes. Mineralized collagen (MC) replicates native bone extracellular matrix but lacks osteoinductive capacity. Platelet-rich plasma (PRP) is a fibrin matrix enriched with growth factors (e.g., VEGF, PDGF, TGF-β1, IGF-1) that promote cell proliferation and osteoblastic differentiation, yet its gel-like form suffers from poor structural integrity in bone defects. Methods: This study investigated whether the combination of PRP and MC produces enhanced effects on osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) and healing of critical-sized bone defects. PRP + MC composites were prepared by immersing MC scaffolds in PRP and evaluated using rat BMSCs Results: The PRP + MC composite significantly enhanced BMSC proliferation at day 7. ALP activity and mineralization were markedly increased, accompanied by significantly upregulated RUNX2 expression (∼5.6-fold vs. control). Micro-CT revealed near-complete defect filling with high-density trabecular architecture. Histologically, the composite group exhibited the highest new bone area (∼75%) and OPN expression, with mature lamellar bone and host integration, whereas controls remained dominated by fibrous scar tissue. Discussion: PRP + MC represents a biomimetic and cost-effective strategy for enhancing bone repair. By combining structural scaffolding with biological stimulation, this composite activates RUNX2-mediated signaling and achieves enhanced regeneration in critical-sized defects, supporting its preclinical potential as an alternative to autologous bone grafting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.